You just read:

Blueprint Medicines Announces Updated Data from Phase 1 ARROW Clinical Trial Showing Broad, Durable Activity of BLU-667 in Advanced RET-Altered Medullary and Papillary Thyroid Cancers

News provided by

Blueprint Medicines Corporation

Oct 06, 2018, 08:50 ET